SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a report that it has made an unsolicited $56 billion bid to acquire eBay, sparking intense community debate over the feasibility of the deal and the potential for massive shareholder dilution. The news has reignited long-standing "meme stock" discussions, with traders actively debating whether this is a strategic move to create a retail powerhouse or a risky gamble that will trigger a short squeeze.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing a significant surge driven by high short interest and institutional accumulation, with community members actively discussing a potential short squeeze ahead of the upcoming earnings report. The stock's recent price appreciation is fueled by strong momentum in the voice AI sector and growing confidence in the company's strategic partnerships and competitive positioning.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors react to a viral Wall Street Journal profile highlighting the company's successful pivot into a high-margin software powerhouse and its critical role in the 'Machine Economy' via QNX and NVIDIA partnerships. The community is actively discussing a potential breakout fueled by consistent profitability, massive royalty backlogs, and growing institutional interest in the company's role as the secure, 'invisible' backbone for autonomous transit and physical AI.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following a report that GameStop is building a significant stake in the company as part of a potential multi-billion dollar acquisition strategy. While retail traders are actively debating the feasibility and financial logic of such a massive takeover, the news has sparked significant volatility and speculation regarding the future of both companies.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae shares are surging following high-profile endorsements from Bill Ackman and Michael Burry, who labeled the stock "stupidly cheap" and highlighted its significant asymmetric upside potential. Investors are actively debating the timing of a potential privatization and uplisting, with community sentiment split between intense optimism over a long-awaited "halo trade" and skepticism regarding whether the recent price action is a pump-and-dump scheme.

SkyAI is an all-in-one AI ecosystem powered by MCP, designed to seamlessly integrate intelligent solutions across industries.

SkyAI

SkyAI is experiencing significant volatility and aggressive trading volume, fueling intense community debate over whether it represents a sustainable momentum play or a short-term speculative pump. Traders are closely monitoring entry points and top-holder activity while comparing the coin's rapid price action to other high-momentum digital assets.

Advanced Biomed, Inc. operates as a holding company with interests in developing biochip technologies. It engages in the research & development of microfluidic biochip technologies and provides tumor diagnosis and treatment technology applications. The company was founded by Yi Lu and Steven I-Fang Cheng in 2014 and is headquartered in Tainan, Taiwan.

Advanced Biomed Inc

Advanced Biomed is trending as traders speculate on a potential short squeeze, fueled by its low-float status and community discussion regarding recent chart activity. Participants are closely watching key technical levels to see if the stock can sustain momentum following recent volatility.

The Toronto-Dominion Bank engages in the provision of financial products and services. It operates through the following segments: Canadian Personal and Commercial Banking, U.S. Retail, Wealth Management and Insurance, Wholesale Banking, Corporate segment. The Canadian Personal and Commercial Banking segment is involved in the provision of deposit, saving, payment, and lending products and advice. It also offers customized products and services to help business owners meet financing, investment, cash management, international trade, and day-to-day banking needs through its network of commercial branches and specialized customer centers. The U.S. Retail segment focuses on personal, business banking, and wealth management operations in the U.S. The Wealth Management and Insurance segment offers wealth and asset management products and advice to retail clients in Canada through the direct investing, advice-based, and asset management businesses. The Wholesale Banking segment serves corporate, government, and institutional clients in key financial markets around the world. The Corporate segment consists of service and control groups, including technology solutions, shared services, treasury and balance sheet management, marketing, human resources, finance, risk management, compliance, anti-money laundering, legal, real estate, and others. The company was founded on February 1, 1955, and is headquartered in Toronto, Canada.

Toronto Dominion Bank

Toronto Dominion Bank is facing intense market scrutiny following its guilty plea to money laundering charges and the imposition of a massive regulatory penalty, including an asset growth cap in the U.S. While some in the community are focused on the long-term dividend yield and historical resilience of the bank, many investors are expressing concerns over the stock's near-term volatility and the potential impact of ongoing regulatory restrictions on future growth.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors aggressively position themselves ahead of upcoming earnings, with the community fueled by expectations of a persistent AI memory supercycle and significant institutional interest. Market participants are actively debating the stock's valuation relative to its explosive growth potential, with intense speculation surrounding call option activity and the potential for a gamma squeeze.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is trending as community members rally behind various meme coins and utility projects within its ecosystem, while debating the broader crypto market's potential for recovery. Traders are actively monitoring the token's price action and staking opportunities, with community sentiment often focused on the balance between long-term accumulation and short-term volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Femasys (NASDAQ:FEMY) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Femasys from a "sell" rating to a "hold" rating in a research note on Friday...

<ul class="summary-bullets"><li>The stake sale comes on the heels of the company increasing its stake in TNF Pharmaceuticals in September by an additional $3 million.&nbsp;</li><li>PharmaCyte said that it plans to continue pursuing value-accretive investment opportunities and disciplined operational management.&nbsp;</li><li>The company said that monetizing its stake in Femasys will help strengthen its financial position.</li></ul> PharmaCyte Biotech, Inc. (PMCB) said on Tuesday that it sold its stake in Femasys Inc. (FEMY), thereby increasing its cash and marketable securities to about $20 million.The company had cash and marketable securities of only about $13.3 million as of the end of July. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.pharmacyte.com/press-releases/detail/319/pharmacyte-biotech-successfully-monetizes-femasys-stake">said</a> that monetizing its stake in Femasys will help strengthen its financial position.Shares of <a href="https://stocktwits.com/symbol/PMCB">PMCB </a>traded 25% higher at the time of writing.<h2 class="st-heading-2">PharmaCyte’s Financial Position</h2>CEO Josh Silverman stated that the successful monetization of the Femasys position demonstrates the effectiveness of the strategic and disciplined capital allocation approach. “We are committed to deploying shareholder capital intelligently, balancing near-term returns with opportunities that can deliver sustained value creation,” he said.Overall, PharmaCyte now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash. The company highlighted its low stock price below $1 and added that it plans to continue pursuing value-accretive investment opportunities and disciplined operational management.The stake sale comes on the heels of the company increasing its stake in Q/C Technologies, formerly known as TNF Pharmaceuticals, in September by an additional $3 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PMCB jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that the news shows the company has ways to generate cash without doing share offerings.<stembedurl>https://stocktwits.com/MadBat/message/637404061</stembedurl>Another expects the stock to cross the $1 threshold.<stembedurl>https://stocktwits.com/cbt2020/message/637412358</stembedurl>PMCB stock fell 48% this year and by about 53% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-slips-after-q4-revenue-guidance-disappoints/cL52NcEREgI">Nio Stock Slips After Q4 Revenue Guidance Disappoints</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

PMCB Stock Jumps 25% After Company Sells Stake In Femasys

PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.

Equity

PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.


<ul class="summary-bullets"><li>Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device.</li><li>The company raised $12 million through convertible notes, with potential total proceeds of $58 million if all warrants are exercised, strengthening its balance sheet.</li><li>Retail investors on Stocktwits turned bullish on the news, calling Femasys a long-term play with disruptive potential in women’s health.</li></ul>Retail chatter around Femasys spiked on Monday following the company’s announcement that it secured U.S. Food and Drug Administration (FDA) approval to advance the final phase of its pivotal trial for FemBloc, a non-surgical permanent birth control device, and raised $12 million in financing that could grow to $58 million if all warrants are exercised.<h2 class="st-heading-2">FDA Clears Final Phase Of FemBloc Trial</h2>Femasys announced FDA approval to resume enrollment for the final phase of the FemBloc pivotal FINALE trial, allowing it to move closer to U.S. Pre-Market Approval (PMA).The Investigational Device Exemption (IDE) approval came following the successful completion of the trial’s first stage, advancing the commercialization of the world’s first non-surgical, permanent birth control in the U.S.FemBloc uses a polymer-based delivery system that blocks the fallopian tubes without incisions or anesthesia, offering a safer and lower-cost alternative to surgical sterilization.<h2 class="st-heading-2">Financing Deal With Potential Upside To $58 Million</h2>Alongside the FDA update, Femasys entered into a private placement agreement with institutional and accredited investors, led by Jorey Chernett, to issue $12 million in senior secured convertible notes and warrants,&nbsp;with the potential to raise total proceeds to $58 million if exercised for cash.The company said proceeds will go toward refinancing debt and advancing&nbsp;the commercialization of its fertility and permanent birth control portfolio.The notes carry an 8.5% annual interest rate and are convertible at $0.73 per share, a 15% premium to the stock’s prior closing price. Warrants carry exercise prices between $0.81 and $1.10 per share, with 10-year terms.<h2 class="st-heading-2">Stocktwits Users Cheer Regulatory Win</h2>On Stocktwits, retail sentiment for Femasys was ‘bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:969/142;" src="https://news.stocktwits-cdn.com/femy_ss_jpg_e7ab6d375e.webp" alt="femy ss.jpg" width="969" height="142"><figcaption>FEMY sentiment and message volume as of November 3 | Source: Stocktwits</figcaption></figure>One user said they viewed Femasys as a long-term play, describing its regulatory progress and disruptive women’s health products as strong growth drivers. The user added that the company’s performance is likely to move “based on fundamentals” rather than hype, noting that women’s health remains an underappreciated sector.<stembedurl>https://stocktwits.com/CoconutNinja/message/634760377</stembedurl>Another user speculated whether the stock would see after-hours upside following the positive news.<stembedurl>https://stocktwits.com/steve04240/message/634739416</stembedurl><a href="https://stocktwits.com/symbol/FEMY">Femasys’ stock</a> has declined 40% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Femasys logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing

Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device.

Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

Femasys (FEMY) delivered earnings and revenue surprises of +11.11% and -48.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Femasys Inc. (FEMY) traded 17% lower on Friday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/30/3091024/0/en/Femasys-Announces-Pricing-of-Underwritten-Public-Offering-and-Concurrent-Private-Placement-with-Gross-Proceeds-of-4-5-Million.html">announced</a> the pricing of an underwritten public offering of 3.6 million shares of its common stock at $0.85 per share.The offer price represents a discount of about 17% from the stock’s closing price on Thursday.The company also announced a separate concurrent private placement of approximately 1.7 million shares of its common stock at the same price as sold to certain existing institutional stockholders of Femasys, as well as a price of $1.02 per share to certain of its directors and officers.The gross proceeds of the public offering and private placement to Femasys are expected to be about $4.5 million.The company stated that it intends to use the net proceeds for the expansion of its commercial efforts, the development of its products and product candidates, general corporate purposes, capital expenditures, working capital, and general and administrative expenses.Both the public offering and the private placement are expected to close on or about June 2 and are subject to the successful completion of customary closing conditions.On Stocktwits, the retail sentiment around Femasys jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_8_59_37_AM_png_3daa1e0a3d.webp" alt="FEMY's Sentiment Meter and Message Volume as of 9:00 a.m. ET on May 30, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>FEMY's Sentiment Meter and Message Volume as of 9:00 a.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the company and said they will buy shares in the short term.<stembedurl>https://stocktwits.com/Mirto/message/616299906</stembedurl>Another user, however, expressed concerns about the stock falling below $1.<stembedurl>https://stocktwits.com/goldenxb/message/616299012</stembedurl><a href="https://stocktwits.com/symbol/FEMY">FEMY stock</a> is down by over 23% this year and by about 28% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-dell-to-build-doe-s-doudna-supercomputer/ch0MD6bRbuG">Nvidia, Dell To Build DOE’s Doudna Supercomputer – ‘Time Machine for Science,’ Says Jensen Huang</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up

The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday.

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

Shares of Femasys Inc. (FEMY) tumbled nearly 14% on Thursday after the company’s 2024 <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.femasys.com/news/news-details/2025/Femasys-Announces-Financial-Results-for-Year-Ended-December-31-2024-and-Provides-Corporate-Update/default.aspx">earnings</a> fell below Wall Street estimates.The company reported a 52% jump in annual sales to $1.62 million compared to 2023, but failed to meet an analyst estimate of $2.71 million, according to FinChat data.The loss per share of $0.85, though lower than the $0.93 reported in 2023, exceeded an estimated loss of $0.80.The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.Femasys said its current cash and cash equivalents, which includes approximately $5.4 million raised subsequent to year-end, will be sufficient to fund its ongoing operations into third quarter of 2025.The company focuses on addressing critical unmet needs in women’s health with a broad, patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products.Femasys CEO Kathy Lee-Sepsick said that the company is focused on commercializing FemaSeed, its first-line infertility treatment, and expects U.S. revenue to increase by about 50% in the first quarter of 2025 compared to the previous quarter.“We are continuing to advance our FemBloc to commercialization in Europe while executing on the clinical pivotal trial for U.S. FDA approval,” she added. FemBloc is the company's non-surgical permanent birth control.On Stocktwits, retail investor sentiment about Femasys dropped slightly in the ‘bullish’ territory (56/100) while message volume dropped from ‘high’ to ‘normal’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:651/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_1_54_06_PM_png_ca980a7546.webp" alt="FEMY's Sentiment Meter and Message Volume as of 2:05 p.m. ET on March 27, 2025 | Source: Stocktwits" width="651" height="151"><figcaption>FEMY's Sentiment Meter and Message Volume as of 2:05 p.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user noted the company’s increase in annual sales and opined that the company is “heading in the right direction for sure.”<stembedurl>https://stocktwits.com/stoneblood/message/609410856</stembedurl>Another user highlighted they were buying the stock.<stembedurl>https://stocktwits.com/Mirto/message/609411502</stembedurl><a href="https://stocktwits.com/symbol/FEMY">FEMY shares</a> have gained over 19% this year but have lost nearly 11% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/microalgo-stock-surges-after-wimi-hologram-cloud-expands-stake/chJ2ah6RbEB">MicroAlgo Stock Surges After WiMi Hologram Cloud Expands Stake, Locking In Shares For 10 Years – Retail Hopes For Another Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic

The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

FEMY
Femasys Inc

Feed

News

Sentiment

Fundamentals

Info

Latest FEMY News

FEMYFemasys Inc